emmarayner, Author at European Medical Journal - Page 2 of 18

Interview: Damian Roland

Damian Roland | Head of Service, Children’s Emergency Department, Leicester Royal Infirmary, UK; Honorary Professor, Population Health Sciences, University of Leicester, UK

Infographic: 5 Key Reasons: All Infants Need Protection from RSV

Infographic: 5 Key Reasons: All Infants Need Protection from RSV. This educational activity is sponsored by Sanofi.

A Review of the Latest Advancements in Ovarian Cancer Care Featured at ESMO 2022

Ovarian cancer is the seventh most commonly diagnosed cancer among females and the most lethal gynaecologic malignancy globally because of its vague presentation, insidious nature, recurrence, and drug resistance.

Interview: Nassir Marrouche

EMJ is proud to present an interview with Nassir Marrouche, a globally renowned electrophysiologist and researcher currently directing a collaborative team of specialists to optimise prediction, prevention, and outcomes for cardiovascular disease (CVD) by pioneering research into digital health (DH) solutions.

Using Behavioural Science to Help Understand Vaccine Hesitancy

This article is based on a Learning Lounge educational session that took place on 22nd October 2022, as part of Infectious Diseases Society of America (IDSA) IDWeek™ 2022 held in Washington, D.C., USA.

Anti-TNF Treatment in Crohn’s Disease Complicated by Intra-abdominal Abscess

Excess production of TNF-α leads to chronic inflammation and tissue damage in immune-mediated inflammatory diseases (IMID) such as Crohn’s Disease (CD), rheumatoid arthritis, and psoriasis. The introduction of anti-TNF agents revolutionised therapy for patients with IMIDs, and two anti-TNFs are currently approved for use in CD in Europe: infliximab and adalimumab.

Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Chaired by Prof. Andrea Necchi, this symposium presented by Prof. Rouprêt and Prof. Retz explores the treatment landscape for muscle-invasive urothelial carcinoma, as well as their perspectives on future treatment landscape.

Targeting FGFR alterations in cholangiocarcinoma and other solid tumours: A new frontier in personalised medicine

Originally presented at ESMO Congress 2022, Incyte’s satellite symposium featured educational presentations from an esteemed faculty of experts including Professor Juan Valle (Co-chair; UK), Dr David Malka (Co-chair; France), Professor Filippo de Braud (Italy), Dr Angela Lamarca (Spain) and Dr Antoine Hollebecque (France).

Dilemmas in breast cancer treatment planning: how understanding tumor biology with MammaPrint and BluePrint can help you

This webinar will educate you on how the biology of a breast tumour reveals additional information that can support choosing the best treatment plan. It will specifically focus on now-a-days clinical dilemmas, like what is the best treatment for pre-menopausal patients, what is the optimal duration of endocrine therapy and how can I find those nasty tumours. The dilemmas are discussed with the help of cases.

Clinical Efficacy and Outcomes of Remibrutinib (LOU064) in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1-Antihistamines: Findings from a Phase IIb Study

As part of the 31st European Academy of Dermatology and Venereology (EADV) Annual Congress held in Milan, Italy, and online, 7th–10th September 2022, five poster presentations outlined results from the Phase IIb study of remibrutinib (LOU064) in patients with chronic spontaneous urticaria inadequately controlled with H1-antihistamines.